Shares of Oryzon Genomics, S.A, (OTCMKTS:ORYZF) have been trading within a narrow range over the past few sessions.
Market Reaction
On Thursday, ORYZF stock ended flat at $2.77 with 5 shares, compared to its average volume of 15 shares. The stock moved within a range of $2.7700 – 2.7700 after opening trade at $2.77.
Earnings Recap
Clinical-stage biopharmaceutical firm, Oryzon Genomics, S.A, (OTCMKTS:ORYZF) on February 7, 2022 came out with financial results for quarter four of 2021 and gave update on recent developments.
Dr Carlos Buesa, Oryzon’s Chief Executive Officer said that the firm has made robust progress on its clinical pipeline in 2021.
Buesa added that Oryzon Genomics has finished enrollment of patients in iadademstat’s Phase II trial and gave a fresh positive clinical data from the trial. He added that the firm has unfolded registrational strategy in AML.
Furthermore, the CEO said that the company reached vital milestones. Vafidemstat’s Phase IIb PORTICO received IND approval from FDA in June and is now recruiting patients in Spain, USA, Germany, Bulgaria as well as Serbia.
The firm confirmed that it had got approval and started recruitment for its vafidemstat’s Phase IIb in schizophrenia, called EVOLUTION.
Along with prestigious KOLs, the firm is progressing on designing of HOPE, first randomized Phase I/II personalized medicine trial. Oryzon has ensured strengthening of permanent presence in US with appointment of two fresh US-based executives.
The CEO also welcomed Sai Nandi as the Global Chief Business Officer for optimising US investor relations as well as corporate relations. Also, Ana Limón has been taken as Senior VP of Clinical Development and Global Medical Affairs for coordinating US clinical activities.
Key Quote
Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “We made strong progress on our clinical pipeline in 2021. In oncology, we completed the full enrollment of patients in iadademstat’s Phase II trial in acute myeloid leukemia (AML) and presented new positive clinical data from this trial, most recently at ASH in December, supporting the strong clinical activity of iadademstat. Also, we have unfolded our registrational strategy in AML and in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) with two new carefully designed trials to start in 2022, FRIDA and STELLAR, that we believe may merit accelerated approval.”
